o/w/o EMULSION CONTAINING LIGNAN COMPOUNDS AND COMPOSITION CONTAINING THE SAME
An O/W/O emulsion composition having at least one of lignan-class compounds dissolved in an internal oil phase is disclosed. This composition can be produced by a process comprising the steps of 1) dissolving at least one of lignan-class compounds in oil or fat to prepare a lignan-class compound dissolving liquid; 2) emulsifying the lignan-class compound dissolving liquid in a water phase to form an O/W emulsion; and 3) further emulsifying the O/W emulsion in an oil phase to prepare an O/W/O emulsion. This is a lignan-class compound containing composition that is enhanced in the amount of bodily absorption of lignan-class compounds.
1 . An O/W/O emulsion composition having at least one of lignan-class compounds dissolved in an internal oil phase.
2 . The O/W/O emulsion composition according to claim 1 , wherein the lignan-class compound is sesamin and/or episesamin.
3 . The O/W/O emulsion composition according to claim 1 , wherein at least one of the internal oil phase, water phase and/or external oil phase contains a surfactant in an amount effective for emulsification.
4 . The O/W/O emulsion composition according to claim 1 , wherein the internal oil phase has an average particle size of 1000 nm or smaller (preferably 500 nm or smaller, and more preferably 300 nm or smaller).
5 . A food composition or an oral pharmaceutical composition that contain the O/W/O emulsion composition according to claim 1 .
6 . An O/W/O emulsion composition comprising an internal oil phase which is emulsified in a water phase to make an O/W emulsion composition which in turn is emulsified in an external oil phase, the internal oil phase containing at least one of lignan-class compounds.
7 . An O/W/O emulsion composition having at least one of lignan-class compounds dissolved in an internal oil phase in a clinically effective amount, said composition optionally containing a surfactant in an amount effective for emulsification, which composition, when administered perorally, enables at least one of lignan-class compounds to be absorbed with a greater area under the blood concentration-time curve (AUC) than when the same quantity of that lignan-class compound is dissolved in the same oil or fat as the internal oil phase and administered perorally under the same conditions.
8 . A process for producing a lignan-class compound containing composition comprising the following steps:
1) dissolving at least one of lignan-class compounds in oil or fat to prepare a lignan-class compound dissolving liquid;
2) emulsifying the lignan-class compound dissolving liquid in a water phase to form an O/W emulsion; and
3) further emulsifying the O/W emulsion in an oil phase to prepare an O/W/O emulsion.
9 . The process according to claim 8 , wherein the lignan-class compound is sesamin and/or episesamin.
10 . A method of improving the amount of bodily absorption of lignan-class compounds comprising the following steps:
1) dissolving at least one of lignan-class compounds in oil or fat to prepare a lignan-class compound dissolving liquid;
2) emulsifying the lignan-class compound dissolving liquid in a water phase to form an O/W emulsion; and
3) further emulsifying the O/W emulsion in an oil phase to prepare an O/W/O emulsion.
11 . The method according to claim 10 , wherein the lignan-class compound is sesamin and/or episesamin.